TY - JOUR T1 - Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study JF - medRxiv DO - 10.1101/2020.04.09.20054031 SP - 2020.04.09.20054031 AU - Olga Nigro AU - Graziella Pinotti AU - Federica De Galitiis AU - Francesca Romana Di Pietro AU - Raffaele Giusti AU - Marco Filetti AU - Melissa Bersanelli AU - Alessandro Lazzarin AU - Paola Bordi AU - Annamaria Catino AU - Pamela Pizzutilo AU - Domenico Galetta AU - Paolo Marchetti AU - Andrea Botticelli AU - Simone Scagnoli AU - Marco Russano AU - Daniele Santini AU - Mariangela Torniai AU - Rossana Berardi AU - Biagio Ricciuti AU - Andrea De Giglio AU - Rita Chiari AU - Alessandro Russo AU - Vincenzo Adamo AU - Marianna Tudini AU - Rosa Rita Silva AU - Elena Bolzacchini AU - Monica Giordano AU - Pietro Di Marino AU - Michele De Tursi AU - Erika Rijavec AU - Michele Ghidini AU - Ilaria Vallini AU - Luigia Stefania Stucci AU - Marco Tucci AU - Laura Pala AU - Fabio Conforti AU - Paola Queirolo AU - Enrica Tanda AU - Francesco Spagnolo AU - Federica Cecchi AU - Sergio Bracarda AU - Serena Macrini AU - Matteo Santoni AU - Nicola Battelli AU - Maria Concetta Fargnoli AU - Giampiero Porzio AU - Alessandro Tuzi AU - Matteo Basilio Suter AU - Corrado Ficorella AU - Alessio Cortellini Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20054031.abstract N2 - Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICI) are lacking.We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in advanced cancer patients. IrAEs were categorized into “early” (≤12 months) and “late” (>12 months).From September 2013 to October 2019, 436 consecutive patients were evaluated. 223 experienced any grade early-irAEs (51.1%), while 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, while 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced G3/G4 irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95%CI: 2.8-4.2), while the median time to onset of late-irAEs was 16.6 months (95%CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (HR = 0.63 [95%CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95%CI: 0.37-1.56], p = 0.452). Also the time-adjusted cumulative risk of death according to both early-irAEs (HR = 0.79 [95%CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95%CI: 0.49-1.74], p = 0.811) did not show statistically significant differences.Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs, and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs.Competing Interest StatementDr. Alessio Cortellini received grants as speaker by MSD and Astra-Zeneca; grant consultancies by BMS, Roche, Novartis, Istituto Gentili and Ipsen. Dr. Melissa Bersanelli received research funding by Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis and Sanofi; she also received honoraria for advisory role and as speaker at scientific events by Bristol-Myers Squibb, Novartis and Pfizer. Dr. Marco Russano received honoraria for scientific events by Roche, Astrazeneca, Bristol-Myers Squibb, Merck Sharp & Dohme and Boehringer Ingelheim. Dr. Raffaele Giusti Advisory Boards/ Honoraria/ Speakers’ fee/ Consultant for: Astra Zeneca, Roche.Funding StatementNo funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe datasets used during the present study are available from the corresponding author upon reasonable request ER -